Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics (NASDAQ: STIM) announced inducement awards under Nasdaq Listing Rule 5635(c)(4) granted to six new non-executive employees on April 29, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neuronetics (NASDAQ: STIM) announced inducement awards under Nasdaq Listing Rule 5635(c)(4) granted to six new non-executive employees on April 29, 2026. The grants comprise a total of 122,400 RSUs across the recipients, with vesting in thirds over three or four years and subject to continued service and the 2020 Inducement Incentive Plan.
The Compensation Committee approved the awards as material inducements to employment; vesting schedules vary by grant and are tied to service anniversaries.
Details
News Market Reaction – STIM
On Apr 30, the first trading day after this news, STIM closed 14.12% above the previous close.
Data tracked by StockTitan Argus for the Apr 30 session.
Key Figures
- RSU grant
- 70,000 RSUs
- Inducement award to Jeffrey Miller under 2020 Inducement Incentive Plan
- Additional RSU grant
- 35,000 RSUs
- Second inducement award to Jeffrey Miller with longer vesting
- Registered shares
- 20,737,061 shares
- Common stock registered for resale under March 17, 2026 shelf prospectus
- CEO 2025 compensation
- $4,365,064
- Total compensation for CEO Keith J. Sullivan in 2025 per DEF 14A
- Workforce reduction
- 5% of employees
- Workforce reduction outlined in April 6, 2026 Form 8-K
- Restructuring charges
- $0.2 million
- Expected Q2 2026 restructuring charges from workforce reduction
- Expected cost savings
- $2.5 million
- Lower end of anticipated annualized cost savings from restructuring
- Shares outstanding
- 69,579,508 shares
- Common shares outstanding as of March 30, 2026 per DEF 14A
Historical Context
-
Set date and time to report Q1 2026 results and host call.
-
Optum/UHC policy change expands NeuroStar TMS access to PMHNPs.
-
Company responds to major holder letter, stressing commitment to value.
-
CFO resignation announcement alongside reaffirmed fiscal 2026 guidance.
-
Largest independent holder urges review of strategic alternatives.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock units financial
inducement incentive plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.
Restricted stock units (“RSUs”)
| Name | Number of Inducement Plan RSUs | Vesting Schedule |
| Jeffrey Miller | 70,000 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Jeffrey Miller | 35,000 | 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Michael Walsh | 600 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Christina Piacentino | 3,000 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Angelo Gonzalez | 2,400 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Lori Flint | 2,400 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Carole Corcoran | 9,000 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (“MDD”) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
References
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.